There are currently 73 clinical trials in Santa Ana, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Syrentis Clinical Research, Apex Research Institute, GSK Investigational Site and Neuropsychiatric Research Center of Orange County. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
NCT05711940
Recruiting
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Syrentis Clinical Research, Santa Ana, California
Conditions: Treatment Resistant Depression
Register for Updates
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
NCT06179108
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives o... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/20/2024
Locations: NRC Research Institute, Santa Ana, California
Conditions: Schizophrenia
Register for Updates
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
NCT05110157
Recruiting
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Neurocrine Clinical Site, Santa Ana, California
Conditions: Schizophrenia
Register for Updates
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT05592275
Recruiting
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Velocity Clinical Research, Coastal Heart Medical Group, Santa Ana, California
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
Register for Updates
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198
Recruiting
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/19/2024
Locations: Southern California Dermatology, Inc., Santa Ana, California
Conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Register for Updates
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
NCT05518149
Recruiting
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI]) in all participants with major depressive disorder (MDD).
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2024
Locations: Syrentis Clinical Research, Santa Ana, California
Conditions: Depressive Disorder, Major
Register for Updates
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
NCT04899336
Recruiting
The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia coli disease (IED) event caused by ExPEC9V O-serotypes.
Gender:
All
Ages:
60 years and above
Trial Updated:
06/18/2024
Locations: Prestige Medical Group, Santa Ana, California
Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Register for Updates
A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
NCT05869773
Recruiting
The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new information regarding BP changes related to differences in sodium content between available oxybates for the treatment of narcolepsy.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/18/2024
Locations: SDS Clinical Trials, Inc., Santa Ana, California
Conditions: Narcolepsy
Register for Updates
Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults
NCT05615220
Recruiting
This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults in the treatment of Tourette's Disorder (TD). The study includes an open-label period followed by double-blind, placebo-controlled, randomized withdrawal period.
Gender:
All
Ages:
6 years and above
Trial Updated:
06/18/2024
Locations: Syrentis Clinical Research, Santa Ana, California
Conditions: Tourette Disorder
Register for Updates
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200
Recruiting
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Gender:
All
Ages:
65 years and above
Trial Updated:
06/18/2024
Locations: Anthos Investigative Site 1076, Santa Ana, California
Conditions: Atrial Fibrillation (AF)
Register for Updates
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869
Recruiting
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Syrentis Clinical Research, Santa Ana, California
Conditions: Atrial Fibrillation
Register for Updates
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05455684
Recruiting
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2024
Locations: Syrentis Clinical Research, Santa Ana, California
Conditions: Depressive Disorder, Major, Anhedonia
Register for Updates